Multiple outcomes of raloxifene evaluation MORE

Yet the pivotal study on raloxifene has been the Multiple Outcomes of Raloxifene Evaluation (MORE), a randomized, double-blind, placebo-controlled trial... 

Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HAP, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 3609-3617... 

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282 637-645... 

Additionally it has been observed that raloxifene reduces the risk of breast cancer by 58-66%, without producing an increased risk of endometrial cancer in postmenopausal women (Cummings et al. 1999 Jordan et al. 1998). The Multiple Outcomes of Raloxifene Evaluation (MORE) clinical trial is particularly eloquent in this regard (Cummings et al. 1999). A total of7704 postmenopausal women (average age 66.5 years) with osteoporosis and without history of breast or endometrial cancer were included. The trial, which was randomized and double-blind, used two doses of raloxifene (60 or 120mg/d) or placebo to as-... 

Raloxifene increases bone mineral density and reduces fracture rates. In trials of 1 to 3 years, raloxifene increased vertebral and hip bone mineral density by 2% to 3% and 1% to 2%, respectively.30 32 In the Multiple Outcomes for Raloxifene Evaluation (MORE) trial, raloxifene decreased the risk of vertebral fractures by 30% in postmenopausal with at least one prior fracture.30 No significant reduction in nonvertebral fractures was reported. 

Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 287 847-857... 

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc 281 2189-2197... 

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001 65(2) 125-34. 

CauleyJA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001 65 125-134. 

The MORE study (Multiple Outcomes of Raloxifene Evaluation) was a multicenter, randomized, double-blind design which followed 7,705 postmenopausal... 

WHI, Women s Health Initiative MORE, Multiple Outcomes of Raloxifene Evaluation CORE, Continuing Outcomes Relevant to Evista. 

---